Positron Emission Tomography/Magnetic Resonance Imaging in Patients



Status:Terminated
Conditions:Lung Cancer, Colorectal Cancer, Skin Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Lymphoma
Therapuetic Areas:Oncology
Healthy:No
Age Range:Any
Updated:4/21/2016
Start Date:February 2012

Use our guide to learn which trials are right for you!

Evaluating Attenuation Correction Methods Applied to PET/MRI

This clinical trial studies positron emission tomography (PET)/magnetic resonance imaging
(MRI) in patients undergoing PET/computed tomography (CT). Diagnostic procedures, such as
PET/MRI, may help doctors diagnose cancer or help doctors predict a patient's response to
treatment

PRIMARY OBJECTIVES:

I. To acquire PET/MRI scans of 100 patients which will be compared with PET/CT scans of the
same subjects. The PET/CT scans will be used to provide the gold standard for evaluating the
image quality and quantitative performance of the PET/MRI scans. After comparison and
evaluation of the imaging capabilities and performance of the sequential PET/MRI imaging
system for these 100 subjects, a second cohort of hundred consecutive subjects may be
necessary and again comparisons made to the current standard of PET imaging, PET/CT. This
validation of the attenuation correction methods and quantitative accuracy of the PET/MRI
device compared to PET/CT will be a continuous iterative process that will result in
optimized performance of the PET/MRI and will be a key step in its becoming available to
other clinical research projects both within the Seidman Cancer Center as well as in other
institutions.

OUTLINE:

After undergoing standard PET/CT, patients undergo PET/MRI.

Inclusion Criteria:

- Only patients who are referred by their physician to have a clinical PET/CT will be
eligible to participate in the study

- we propose to obtain a second PET/MRI on 100 patients after their clinical PET/CT
imaging that spans several disease categories and includes the following cancers:
lung, colon, melanoma, head/neck and lymphoma

- In addition to oncology patients, we anticipate imaging a subset of non-cancer
patients who will also be imaged subsequent to their clinical PET/CT who will be
referrals from neurology and cardiology

- All subjects will be at least 18 years old, or if under 18, parents or guardians must
give consent

- Subjects must be stable and have experienced no adverse events from previous clinical
PET/CT examination

Exclusion Criteria:

- Subjects who do not meet the above inclusion criteria

- Subjects unwilling or unable to sign the informed consent form

- Subjects who are cognitively impaired and thus unable to give informed consent

- Subjects unable to undergo MRI scanning due to exclusion via University Hospital Case
Medical Center (UHCMC) MRI restrictions (e.g. implanted metallic or electronic
devices, hip or other joint replacements, history of kidney disease, unacceptable
creatinine or glomerular filtration rate [GFR], etc)

- Patients who are pregnant
We found this trial at
1
site
11100 Euclid Ave
Cleveland, Ohio 44106
(216) 844-2273
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center We all know...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials